loader

neo:awkn

LATEST ARTICLES
awakn life sciences inc
psychedelics investing

Awakn Life Sciences Announces Closing of Private Placement

Awakn Life Sciences Signs Its Third Licensing Partnership Agreement in North America, and First in New York
psychedelics investing

Awakn Life Sciences Signs Its Third Licensing Partnership Agreement in North America, and First in New York

Awakn Life Sciences Secures Funding to Expand Nordic Commercial Operations
psychedelics investing

Awakn Life Sciences Secures Funding to Expand Nordic Commercial Operations

Awakn Life Sciences Reports Strong Q2 2022 Results
psychedelics investing

Awakn Life Sciences Reports Strong Q2 2022 Results

Awakn Life Sciences Signs Drug Development Agreement with Catalent for Zydis Technology to Conduct Feasibility Studies to Improve Differentiation of Its MDMA Program
psychedelics investing

Awakn Life Sciences Signs Drug Development Agreement with Catalent for Zydis Technology to Conduct Feasibility Studies to Improve Differentiation of Its MDMA Program

Awakn Life Sciences Signs Agreement with a Leading Drug Development Company to Deepen IP Moat for Its Lead Program
psychedelics investing

Awakn Life Sciences Signs Agreement with a Leading Drug Development Company to Deepen IP Moat for Its Lead Program

Awakn Life Sciences Signs Second Licensing Partnership Agreement and Expands Commercial Operations Into Canada
psychedelics investing

Awakn Life Sciences Signs Second Licensing Partnership Agreement and Expands Commercial Operations Into Canada

 Revitalist Partners with Awakn Life Sciences as First Licensee in the United States to begin Redefining Treatment for Addiction, Recovery, and Relapse Prevention in the Psychedelic Space
psychedelics investing

 Revitalist Partners with Awakn Life Sciences as First Licensee in the United States to begin Redefining Treatment for Addiction, Recovery, and Relapse Prevention in the Psychedelic Space

Awakn Life Sciences Expands Commercial Operations into the U.S. - First Licensing Partnership Agreement with Revitalist
psychedelics investing

Awakn Life Sciences Expands Commercial Operations into the U.S. - First Licensing Partnership Agreement with Revitalist

Awakn Life Sciences' Phase III Trial Approved for Approximately CA$2.5 Million Funding from UK State Covering 66% of Costs
psychedelics investing

Awakn Life Sciences' Phase III Trial Approved for Approximately CA$2.5 Million Funding from UK State Covering 66% of Costs

Awakn Life Sciences Provides a Business and Corporate Update
psychedelics investing

Awakn Life Sciences Provides a Business and Corporate Update

Awakn Life Sciences Receives UK State Funding to Identify Optimal Pathway to Market in UK & US for Its Lead Clinical Development Program - Ketamine-Assisted Therapy for Alcohol Use Disorder
psychedelics investing

Awakn Life Sciences Receives UK State Funding to Identify Optimal Pathway to Market in UK & US for Its Lead Clinical Development Program - Ketamine-Assisted Therapy for Alcohol Use Disorder

Latest News

More News

Outlook Reports

Resource
Tech
Life Science

Browse Companies

Resource
Tech
Life Science
MARKETS
COMMODITIES
CURRENCIES